ClinicalTrials.gg
CompletedNCT03826550Updated Feb 1, 2019

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

A Phase 3 interventional study of Diclofenac Sodium Gel and Solaraze 3% Topical Gel in Actinic Keratoses, sponsored by Encube Ethicals Pvt. Ltd.. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-01.

Sponsored by Encube Ethicals Pvt. Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2018, 8 years 4 months ago, and no results have been posted to the registry.
  • Registered 1 year after the study started (first participant enrolled Jan 2018, registered Jan 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
655
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Keratosis, Actinic with a site in United States — 15 open to participants now, 20 under way, 4 of them phase 3. Keratosis, Actinic · United States.

Enrollment
4th of 152
655 · median 73
Started
2018
with 4 others
Phase 3
44 of 165
3 open now
Registered
128th of 165
by date

Among the 165 studies in Keratosis, Actinic with a site in United States, this one is the 4th largest by enrollment of the 152 interventional ones that give a count, is one of 5 that started in 2018, is one of 44 in phase 3, and was the 128th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

15 of the 165 studies in Keratosis, Actinic with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Keratosis, Actinic with a site in United States, or all of them as a file.
02

Study summary

Therapeutic Equivalence of Diclofenac Sodium Gel 3% and Solaraze ®, in the treatment of Actinic Keratosis

Read the detailed description

A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% (Encube Ethicals) Compared to Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharmaceuticals Inc.) in the Treatment of Actinic Keratosis

03

Conditions studied

  • Actinic Keratoses

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Institutional Review Board (IRB)-approved form that meets all criteria of current Food and Drug Administration regulations.
  2. Male or non-pregnant, non-lactating female, 18 years of age or older.
  3. Diagnosis of AK with at least five and no more than ten clinically typical, visible, discrete, non-hyperkeratotic, non-hypertrophic AK lesions, each at least 4 mm in diameter, contained within a contiguous 25 cm2 treatment area on the face and/or bald scalp.
  4. Females of must not be pregnant or lactating at Visit 1 (as confirmed by a negative urine pregnancy test with a sensitivity of less than 50 mIU/ mL or equivalent units of human chorionic gonadotropin). Women of childbearing potential must agree to the use of a reliable method of (e.g., total abstinence, intrauterine device, a double-barrier method, oral, transdermal, injected, or implanted non-hormonal or hormonal contraceptive) throughout the study. Female patients using hormonal contraceptives should have been on the same product/dosing regimen for at least 28 days before Visit 1 and should not change this regimen during the study. A sterile sexual partner is not considered an adequate form of birth control.
  5. Skin pigmentation that will allow discernment of erythema.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant, lactating or planning to become pregnant during the study period.
  2. Active gastrointestinal ulceration or bleeding.
  3. Current evidence or history of severe renal or hepatic impairment.
  4. Known allergy or to diclofenac, benzyl alcohol, polyethylene glycol monomethyl ether 359, hyaluronate sodium or other in the test, reference or vehicle gel.
  5. Known allergy or hypersensitivity to other NSAIDs, including aspirin.
  6. Presence of atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, eczema, psoriasis, rosacea, sunburn, exfoliative dermatitis, open or recent skin wounds, active infections or other possible skin conditions on the face or bald scalp that in the Investigator's opinion would interfere with the study assessments or put the patient at risk.
  7. Use of oral isotretinoin within six months before randomization.
  8. Use within six months before Visit 1 on the face or bald scalp of 1) chemical peel, 2) dermabrasion, 3) laser abrasion, 4) PUVA (psoralen plus ultraviolet A) therapy, or 5) UVB therapy.
  9. Use within one month before Visit 1 on the face or bald scalp of 1) cryodestruction or chemodestruction, 2) curettage, 3) photodynamic therapy, 4) surgical excision, 5) topical 5-fluorouracil, 6) topical , 7) topical diclofenac, 8) topical imiquimod, 9) topical retinoids, or 10) other treatments for AK including glycolic acids or over the- counter (OTC) products containing retinol, alpha or beta hydroxy acids. The occasional use of ophthalmic, intranasal or inhaled corticosteroids (e.g., management of allergic conjunctivitis) is acceptable and not reason for exclusion. Use of inhaled corticosteroids for the management of chronic and stable conditions (e.g., persistent asthma and [COPD]) is acceptable as long as it has been on a stable dose for a minimum of three months before the start of the study and up to 1 mg/day.
  10. Use within one month before Visit 1 of 1) immunomodulators or therapies, 2) interferon, 3) systemic corticosteroids or 4) cytotoxic drugs.
  11. Receipt of 5-Fluorouracil or other systemic cancer chemotherapy within 6 months before Visit 1.
  12. Any condition, medical, psychological, or social, that, in the Investigator's opinion, would interfere with participation in the study or put the patient at risk.
  13. Inability to understand the requirements of the study and the relative information or are unable or not willing to comply with the study protocol.
  14. Receipt of any drug as part of a research study within 30 days before Visit 1.
  15. Employees of the Investigator or research center or their immediate family members.
  16. Patients who have participated in this study previously.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
655 participants (actual)

Study arms

  • Experimental
    Diclofenac Sodium Gel3%

    Diclofenac Sodium Gel 3%, dosed twice daily for 60 days.

    Drug: Diclofenac Sodium Gel

  • Active comparator
    Solaraze

    Solaraze Gel dosed twice daily for 60 days.

    Drug: Solaraze 3% Topical Gel

  • Placebo comparator
    Placebo

    Placebo Gel dosed twice daily for 60 days.

    Other: Placebo

Interventions

  • Twice daily for 60 days. Each patient is expected to receive 120 doses

  • DrugSolaraze 3% Topical Gel

    Drug pages: Diclofenac · Diclofenac Sodium Gel

    Twice daily for 60 days. Each patient is expected to receive 120 doses

  • OtherPlacebo

    Twice daily for 60 days. Each patient is expected to receive 120 doses

06

What researchers measure

Primary outcomes

  1. proportion of patients in each treatment group with 100% clearance of all AK Lesions

    Time frame: Day 90 (30 days after completion of a 60 day treatment)

  2. Superiority of the test and reference products against the placebo

    Time frame: Day 90 (30 days after completion of a 60 day treatment)

07

Study locations

24 sites
  • Dermatology Trial Associates
    Bryant, Arkansas 71011, United States
  • West Coast Research
    San Ramon, California 94582, United States
  • Universal Medical and Research Center, LLC
    Coral Gables, Florida 33134, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32256, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Multi-Speciality Research Associates, Inc.
    Lake City, Florida 32055, United States
  • FXM Research
    Miami, Florida 33175, United States
  • FXM Research Miramar
    Miramar, Florida 33027, United States
  • Ormond Medical Arts Pharmaceutical Research Center
    Ormond Beach, Florida 32174, United States
  • Moore Clinical Research
    Tampa, Florida 33618, United States
  • Forward Clinical Trials
    Tampa, Florida 33624, United States
  • Northwest Clinical Trials
    Boise, Idaho 82704, United States
  • DS Research
    New Albany, Indiana 47150, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • DTRL, Inc.
    Henderson, Nevada 89052, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Sterling Research Group
    Cincinnati, Ohio 45246, United States
  • DermDox Centers for Dermatology
    Hazleton, Pennsylvania 18201, United States
  • PEAK Research, LLC
    Upper Saint Clair, Pennsylvania 15241, United States
  • Anderson Dermatology
    Anderson, South Carolina 29621, United States
  • Greenville Dermatology, LLC
    Greenville, South Carolina 29607, United States
  • Sirius Clinical Research, LLC
    Austin, Texas 78759, United States
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jun 2018, 5 months.

Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2019
First posted
Feb 1, 2019
StartActual
Jan 12, 2018
Primary completionActual
Jun 30, 2018
CompletionActual
Jul 3, 2018
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03826550
Lead sponsor
Encube Ethicals Pvt. Ltd.
Collaborators
Novum Pharmaceutical Research Services
Responsible party
Sponsor
First posted
Feb 1, 2019
Start date
Jan 12, 2018
Primary completion
Jun 30, 2018
Completion
Jul 3, 2018
Last update
Feb 1, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diclofenac Sodium Gel

Start the discussion